Amryt Pharma plc – LSE:AMYT.L

Amryt Pharma stock price today

GBP 152.5
+9.5
+6.64%
Financial Health
0
1
2
3
4
5
6
7
8
9

Amryt Pharma stock price monthly change

+2.88%
month

Amryt Pharma stock price quarterly change

-20.78%
quarter

Amryt Pharma stock price yearly change

-26.67%
year

Amryt Pharma key metrics

Market Cap
 N/A
Enterprise value
 37.88B
P/E
 -0.04
EV/Sales
 180.19
EV/EBITDA
 -2258.88
Price/Sales
 1.79
Price/Book
 1.23
PEG ratio
 N/A
EPS
 -0.47
Revenue
 210.23M
EBITDA
 -16.77M
Income
 -87.53M
Revenue Q/Q
 14.58%
Revenue Y/Y
 16.55%
Profit margin
 -41.64%
Oper. margin
 -11.11%
Gross margin
 49.19%
EBIT margin
 -11.11%
EBITDA margin
 -7.98%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Amryt Pharma stock price history

Amryt Pharma stock forecast

Amryt Pharma financial statements

Profit Margin

Amryt Pharma plc (LSE:AMYT.L): Profit margin
Dec 2020 42.52M -46.99M -110.51%
Mar 2021 48.43M -16.53M -34.14%
Jun 2021 62.76M -6.79M -10.83%
Sep 2021 56.51M -17.20M -30.45%
AMYT.L income statement history

Debt to Assets

Amryt Pharma plc (LSE:AMYT.L): Debt to assets
Dec 2020 536591000 470.44M 87.67%
Mar 2021 521971000 467.60M 89.58%
Jun 2021 533663000 484.34M 90.76%
Sep 2021 855464000 549.44M 64.23%
AMYT.L balance sheet history

Cash Flow

Amryt Pharma plc (LSE:AMYT.L): Cash Flow
Dec 2020 5.77M -1.35M 33.06M
Mar 2021 2.74M -486K -1.85M
Jun 2021 29.69M -310K -4.89M
Sep 2021 -124.33M 107.81M -1.75M
AMYT.L cash flow history

Amryt Pharma alternative data

Amryt Pharma
Employees

Amryt Pharma plc (LSE:AMYT.L): Employee count
Aug 2023 182
Sep 2023 182
Oct 2023 182
Nov 2023 182
Dec 2023 182
Jan 2024 182
Feb 2024 182
Mar 2024 182
Apr 2024 182
May 2024 182
Jun 2024 182
Jul 2024 182

Amryt Pharma other data

Amryt Pharma
Executives

Insider Compensation
Dr. Joseph A. Wiley (1971) Chief Executive Officer & Director
 $1,720,000
Mr. Rory P. Nealon (1968) Chief Financial Officer, Chief Operating Officer & Company Sec.
 $931,000

Frequently Asked Questions (FAQ)

  • What's the price of Amryt Pharma stock today?

    One share of Amryt Pharma stock can currently be purchased for approximately $152.5.

  • When is Amryt Pharma's next earnings date?

    Unfortunately, Amryt Pharma's (AMYT.L) next earnings date is currently unknown.

  • Does Amryt Pharma pay dividends?

    No, Amryt Pharma does not pay dividends.

  • What is Amryt Pharma's stock symbol?

    Amryt Pharma plc is traded on the LSE under the ticker symbol "AMYT.L".

  • What is Amryt Pharma's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Amryt Pharma?

    Shares of Amryt Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Amryt Pharma's key executives?

    Amryt Pharma's management team includes the following people:

    • Dr. Joseph A. Wiley Chief Executive Officer & Director(age: 54, pay: $1,720,000)
    • Mr. Rory P. Nealon Chief Financial Officer, Chief Operating Officer & Company Sec.(age: 57, pay: $931,000)

  • How many employees does Amryt Pharma have?

    As Jul 2024, Amryt Pharma employs 182 workers.

  • When Amryt Pharma went public?

    Amryt Pharma plc is publicly traded company for more then 18 years since IPO on 27 Apr 2007.

  • What is Amryt Pharma's official website?

    The official website for Amryt Pharma is amrytpharma.com.

  • How can i contact Amryt Pharma?

    Amryt Pharma can be reached via phone at +44 20 3415 5730.

Amryt Pharma company profile:

Amryt Pharma plc

amrytpharma.com
Exchange:

LSE

Full time employees:

182

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

+44 20 3415 5730
Ivybridge House, 1 Adam Street
LONDON, 4

:
ISIN: GB00BKLTQ412
CUSIP: G0R1NP101